Literature DB >> 28670657

Risk factors for new-onset shunt-dependency after craniotomies for intracranial tumors in adult patients.

Sayied Abdol Mohieb Hosainey1, Benjamin Lassen2,3, John K Hald2,4, Eirik Helseth2,5, Torstein R Meling2,5.   

Abstract

The risk of developing a de novo shunt-dependent hydrocephalus (HC) after undergoing a craniotomy for brain tumor in adult patients is largely unknown. All craniotomies for intracranial tumors at Oslo University Hospital in adult patients ≥18 years of age during a 10-year period (2004-2013) were included. None were lost to follow-up. Patients who developed a shunt-dependent HC were identified by cross-linking our prospectively collected tumor database to patients with a NCSP surgical procedure code of hydrocephalus (AAF). Patients with pre-existing HC or ventriculoperitoneal (VP) shunts were excluded from the study. A total of 4401 craniotomies were performed. Of these, 46 patients (1.0%) developed de novo postoperative HC requiring a VP shunt after a median of 93 days (mean 115 days, range 6-442). Median age was 62.0 years (mean 58.9 years, range 27.3-80.9) at time of VP shunt surgery. Patients without pre-existing HC had a 0.2% (n = 8/4401) risk of becoming VP shunt dependent within 30 days and 0.5% (n = 22/4401) within 90 days. Age, sex, tumor location, primary/secondary surgery, and radiotherapy were not associated with VP shunt dependency. Choroid plexus tumors and craniopharyngiomas had increased risk of VP shunt dependency. In this large, contemporary, single-institution consecutive series, the risk of postoperative shunt-dependency after craniotomies for brain tumors without pre-existing HC was very low. This is the largest study with regards to de novo postoperative shunt-dependency after craniotomies for patients with intracranial tumors and can serve as a benchmark for future studies.

Entities:  

Keywords:  Brain tumor; Complications; Craniotomy; De novo hydrocephalus; Postoperative hydrocephalus; Ventriculoperitoneal shunt

Mesh:

Year:  2017        PMID: 28670657     DOI: 10.1007/s10143-017-0869-1

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  35 in total

1.  Postoperative hydrocephalus in cranial base surgery.

Authors:  D H Duong; S O'malley; L N Sekhar; D G Wright
Journal:  Skull Base Surg       Date:  2000

2.  Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma.

Authors:  G Evren Keles; Edward F Chang; Kathleen R Lamborn; Tarik Tihan; Chih-Ju Chang; Susan M Chang; Mitchel S Berger
Journal:  J Neurosurg       Date:  2006-07       Impact factor: 5.115

3.  Hydrocephalus in radiation leukoencephalopathy: results of ventriculoperitoneal shunting.

Authors:  B Thiessen; L M DeAngelis
Journal:  Arch Neurol       Date:  1998-05

4.  Delayed hydrocephalus after resection of supratentorial malignant gliomas.

Authors:  G Marquardt; M Setzer; J Lang; V Seifert
Journal:  Acta Neurochir (Wien)       Date:  2002-03       Impact factor: 2.216

5.  Management of hydrocephalus associated with vestibular schwannoma and other cerebellopontine angle tumors.

Authors:  F Pirouzmand; C H Tator; J Rutka
Journal:  Neurosurgery       Date:  2001-06       Impact factor: 4.654

6.  Cerebrospinal fluid disturbances after 381 consecutive craniotomies for intracranial tumors in pediatric patients.

Authors:  Sayied Abdol Mohieb Hosainey; Benjamin Lassen; Eirik Helseth; Torstein R Meling
Journal:  J Neurosurg Pediatr       Date:  2014-10-17       Impact factor: 2.375

7.  Predicting postoperative hydrocephalus in 227 patients with skull base meningioma.

Authors:  Jan-Karl Burkhardt; Pascal O Zinn; Muriel Graenicher; Alejandro Santillan; Oliver Bozinov; Ekkehard M Kasper; Niklaus Krayenbühl
Journal:  Neurosurg Focus       Date:  2011-05       Impact factor: 4.047

8.  An analysis of factors determining the need for ventriculoperitoneal shunts after posterior fossa tumor surgery in children.

Authors:  D J Culley; M S Berger; D Shaw; R Geyer
Journal:  Neurosurgery       Date:  1994-03       Impact factor: 4.654

9.  Independent association of extent of resection with survival in patients with malignant brain astrocytoma.

Authors:  Matthew J McGirt; Kaisorn L Chaichana; Muraya Gathinji; Frank J Attenello; Khoi Than; Alessandro Olivi; Jon D Weingart; Henry Brem; Alf Redo Quiñones-Hinojosa
Journal:  J Neurosurg       Date:  2009-01       Impact factor: 5.115

10.  Pathophysiology of increased cerebrospinal fluid pressure associated to brain arteriovenous malformations: The hydraulic hypothesis.

Authors:  Sandro Rossitti
Journal:  Surg Neurol Int       Date:  2013-03-28
View more
  5 in total

1.  The effect of tumor removal via craniotomies on preoperative hydrocephalus in adult patients with intracranial tumors.

Authors:  Sayied Abdol Mohieb Hosainey; Benjamin Lassen; John K Hald; Eirik Helseth; Torstein R Meling
Journal:  Neurosurg Rev       Date:  2018-08-17       Impact factor: 3.042

2.  Management of Posterior Fossa Tumors in Adults Based on the Predictors of Postoperative Hydrocephalus.

Authors:  Chengda Zhang; Tingbao Zhang; Lingli Ge; Zhengwei Li; Jincao Chen
Journal:  Front Surg       Date:  2022-06-01

3.  Long-term risk of shunt failure after brain tumor surgery.

Authors:  Sayied Abdol Mohieb Hosainey; Benjamin Lassen Lykkedrang; Torstein R Meling
Journal:  Neurosurg Rev       Date:  2021-10-29       Impact factor: 3.042

4.  Hydrocephalus Shunting in Supratentorial Glioblastoma: Functional Outcomes and Management.

Authors:  Amir El Rahal; Debora Cipriani; Christian Fung; Marc Hohenhaus; Lukas Sveikata; Jakob Straehle; Mukesch Johannes Shah; Henrik Dieter Heiland; Jürgen Beck; Oliver Schnell
Journal:  Front Oncol       Date:  2022-02-09       Impact factor: 6.244

5.  Risk of early failure of VP shunts implanted for hydrocephalus after craniotomies for brain tumors in adults.

Authors:  Sayied Abdol Mohieb Hosainey; John K Hald; Torstein R Meling
Journal:  Neurosurg Rev       Date:  2021-04-27       Impact factor: 2.800

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.